Skip to content

Masitinib-loaded poly(lactic-co-glycolic acid) nanoparticles reinstate lysosomal acidification and drive immunomodulation in Alzheimer's disease.

Nov 2026 · Journal of Controlled Release · pp. 115518 · 0 citations · 32 references
Medicine

Abstract

Alzheimer's disease (AD) poses a formidable therapeutic challenge due to its intricate pathological mechanisms and the blood-brain barrier (BBB). Via transcriptomic analyses and experimental validation, we identify that a malignant neuro-immune pathological cycle, driven by neuronal lysosomal acidification dysfunction and microglial immune activation, potently accelerates AD pathogenesis. Then, we engineer a simple bifunctional intranasal delivery system (PLGA@M) by loading masitinib into poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Following intranasal administration, PLGA@M bypasses the BBB to enter the brain directly via olfactory and trigeminal nerves. PLGA degrades to release acidic moieties, lowering lysosomal pH and restoring autophagic flux, while masitinib inhibits microglial colony stimulating factor 1 receptor signaling, attenuating microglial proliferation, excessive activation and neuroinflammation. Behavioral assays confirm that PLGA@M markedly reverses cognitive deficits in AD mice. This system upgrades PLGA from a mere carrier to a therapeutic component, featuring simplicity, high efficiency and great clinical translation potential.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.